Neurogenerative disease drug developer Vigil Neuroscience sees stock rally 19%
Mikko Lemola/iStock via Getty Images         
Vigil Neuroscience (VIGL), which held a $98M initial public offering in January, saw its stock soar 19% in early trading Tuesday.  Shares of the biotech group opened at $3.37, quickly plunging to a low of $2.88 before rebounding. The stock recently changed hands at $3.27, up 19%, at approximately 10:35 a.m.   VIGL went public on Jan. 7, pricing 7M shares at $14 per share to raise around $98M.   The company is developing novel therapeutics for neurogenerative diseases withÂ assets in-licensed from Amgen (AMGN).